Amgen's Phase 3 trial of bemarituzumab plus chemo met its survival goal in FGFR2b+ gastric cancer, with full data expected ...

FDA raised safety concerns for Vyvgart Hytrulo in CIDP, while Argenx moves ARGX-119 into late-stage trials for rare neuromuscular disease.

Amgen said a Phase 3 trial of its gastric cancer treatment, bemarituzumab, met its primary endpoint of overall survival at a pre-specified interim analysis.

Protagonist Therapeutics is taking aim directly at Eli Lilly's obesity treatment with a newly announced drug that uses the same mechanism.

Expedia's first quarter results were met with a negative market reaction after the company missed Wall Street’s revenue ...

Europe’s industrial and energy transition is creating long-duration opportunities in infrastructure, utilities and renewables ...

Brokerage JPMorgan expects EV giant Tesla Inc. (TSLA) to report second-quarter deliveries below the consensus estimate while ...

Mirae Asset Global Investments trimmed its Amgen holdings by 1.5% in the first quarter, selling 7,398 shares. This reduction ...

RedJay Asset Management purchased $1.27 million worth of Regeneron Pharmaceuticals stock in Q1, joining several other major ...